Well, it certainly has been a long time since I’ve posted anything. So much has happened. I thought it had been longer than I thought, I believe my last post was September 2016. 2,163 more words
Tags » Renal Cell Carcinoma
San Francisco-based drug discovery company Exelixis is to collaborate with Japanese pharma giant Takeda in the development of Exelixis’ lead cancer candidate cabozantinib.
Cabozantinib is a tyrosine kinase inhibitor for both c-Met and VEGFR2 molecules, both of which have been shown to have key roles in tumour growth, metastasis, and angiogenesis (the formation of new blood vessels). 329 more words
Silencing communication pathways between cancer cells could help prevent tumour growth, according to new findings.
The study, carried out by researchers at the Barts Cancer Institute, found that by blocking a molecule called CCR4 – a protein known to be over-expressed in several types of cancer – led to a reduction in tumour growth. 116 more words
CC: 2 days of L knee pain and swelling
ID: 58 yo homeless male with alcohol abuse and seizure disorder presents with 2 days of L knee pain and swelling. 234 more words
Ipsen and its partner Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). 692 more words